Browsing by Author "Cordeiro C.R."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
    (European Respiratory Society, 2016) Bousquet J.; Barbara C.; Bateman E.; Bel E.; Bewick M.; Chavannes N.H.; Cruz A.A.; Haahtela T.; Hellings P.W.; Khaltaev N.; Carlsen K.L.; Muraro A.; Cordeiro C.R.; Rosado-Pinto J.; Samolinski B.; Strandberg T.; Valiulis A.; Yorgancioglu A.; Zuberbier T.; Adcock I.; Addis A.; Agache I.; Agusti A.; Alonso A.; Annesi Maesano I.; Anto J.M.; Bachert C.; Baena-Cagnani C.; Bai C.; Baigenzhin A.; Barnes P.J.; Beck L.; Bedbrook A.; Benezet O.; Bennoor K.S.; Benson M.; Bernabeu-Wittel M.; Bindslev Jensen C.; Blain H.; Blasi F.; Bonini M.; Bonini S.; Boulet L.P.; Bourdin A.; Bourret R.; Bousquet P.J.; Brightling C.E.; Briggs A.; Brozek J.; Buhl R.; Bush A.; Caimmi D.; Calderon M.; Calverley P.; Camargos P.; Camuzat T.; Canonica G.W.; Carlsen K.H.; Casale T.B.; Cazzola M.; Cepeda Sarabia A.M.; Cesario A.; Chen Y.Z.; Chkhartishvili E.; Chiron R.; Chuchalin A.; Chung K.F.; Cox L.; Crooks G.; Crooks M.G.; Custovic A.; Dahl R.; Dahlen S.E.; De Blay F.; Dedeu T.; Deleanu D.; Demoly P.; Devillier P.; Didier A.; Dinh Xuan A.T.; Djukanovic R.; Dokic D.; Douagui H.; Dubakiene R.; Eglin S.; Elliot F.; Emuzyte R.; Fabbri L.; Fink-Wagner A.; Fletcher M.; Fokkens W.J.; Fonseca J.; Franco A.; Frith P.; Furber A.; Gaga M.; Gamkrelidze A.; Garcia Aymerich J.; González-Díaz S.; Gouzi F.; Garcés J.; Guzmán M.A.; Harrison D.; Hayot M.; Heaney L.; Heinrich J.; Hooper J.; Humbert M.; Hyland M.; Iaccarino G.; Jakovenko D.; Jardim J.; Jeandel C.; Jenkins C.; Johnston S.L.; Jonquet O.; Joos G.; Jung K.S.; Kalayci O.; Karunanithi S.; Keil T.; Kolek V.; Kowalski M.; Kull I.; Kuna P.; Kvedariene V.; Le L.T.; Louis R.; MacNee W.; Mair A.; Manning P.; Manuel Keenoy M.E.; Majer I.; Masjedi M.R.; Melén E.; Melo Gomes E.; Menzies-Gow A.; Mercier G.; Mercier J.; Michel J.P.; Miculinic N.; Mihaltan F.; Milenkovic B.; Molimard M.; Momas I.; Montilla-Santana A.; Morais Almeida M.; Morgan M.; N'Diaye M.; Nafti S.; Nekam; Neou A.; Nicod L.; O'Hehir R.; Ohta K.; Paggiaro P.; Palkonen S.; Palmer S.; Papadopoulos N.G.; Papi A.; Passalacqua G.; Pavord I.; Pedersen S.; Pigearias B.; Plavec D.; Postma D.S.; Price D.; Rabe K.F.; Radier Pontal F.; Redon J.; Rennard S.; Roberts J.; Robine J.M.; Roca J.; Roche N.; Rodenas F.; Roggeri A.; Rolland C.; Ryan D.; Sanchez-Borges M.; Schünemann H.J.; Sheikh A.; Shields M.; Siafakas N.; Sibille Y.; Similowski T.; Small I.; Sola-Morales O.; Sooronbaev T.; Stelmach R.; Sterk P.J.; Stiris T.; Sud P.; Tellier V.; To T.; Todo Bom A.; Triggiani M.; Valenta R.; Valero A.L.; Valovirta E.; Vandenplas O.; Van Ganse E.; Vasankari T.; Vestbo J.; Vezzani G.; Viegi G.; Visier L.; Vogelmeier C.; Vontetsianos T.; Wagstaff R.; Wallaert B.; Wahn U.; Whalley B.; Wickman M.; Williams D.; Wilson N.; Yawn B.P.; Yiallouros P.; Yusuf O.; Zar H.J.; Zhong N.; Zidarn M.
    [No abstract available]
  • No Thumbnail Available
    Item
    Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening
    (European Respiratory Society, 2023) Ward B.; Vašáková M.K.; Cordeiro C.R.; Yorgancioğlu A.; Chorostowska-Wynimko J.; Blum T.G.; Kauczor H.-U.; Samarzija M.; Henschke C.; Wheelock C.; Grigg J.; Andersen Z.J.; Koblížek V.; Májek O.; Odemyr M.; Powell P.; Seijo L.M.
    [No abstract available]
  • No Thumbnail Available
    Item
    Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study
    (Elsevier Ltd, 2023) Sousa-Pinto B.; Jácome C.; Pereira A.M.; Regateiro F.S.; Almeida R.; Czarlewski W.; Kulus M.; Shamji M.H.; Boulet L.-P.; Bonini M.; Brussino L.; Canonica G.W.; Cruz A.A.; Gemicioglu B.; Haahtela T.; Kupczyk M.; Kvedariene V.; Larenas-Linnemann D.; Louis R.; Niedoszytko M.; Pham-Thi N.; Puggioni F.; Romantowski J.; Sastre J.; Scichilone N.; Taborda-Barata L.; Ventura M.T.; Vieira R.J.; Agache I.; Bedbrook A.; Bergmann K.C.; Amaral R.; Azevedo L.F.; Bosnic-Anticevich S.; Brusselle G.; Buhl R.; Cecchi L.; Charpin D.; Loureiro C.C.; de Blay F.; Del Giacco S.; Devillier P.; Jassem E.; Joos G.; Jutel M.; Klimek L.; Kuna P.; Laune D.; Luna Pech J.; Makela M.; Morais-Almeida M.; Nadif R.; Neffen H.E.; Ohta K.; Papadopoulos N.G.; Papi A.; Pétré B.; Pfaar O.; Yeverino D.R.; Cordeiro C.R.; Roche N.; Sá-Sousa A.; Samolinski B.; Sheikh A.; Ulrik C.S.; Usmani O.S.; Valiulis A.; Vandenplas O.; Vieira-Marques P.; Yorgancioglu A.; Zuberbier T.; Anto J.M.; Fonseca J.A.; Bousquet J.
    Background: Validated questionnaires are used to assess asthma control over the past 1–4 weeks from reporting. However, they do not adequately capture asthma control in patients with fluctuating symptoms. Using the Mobile Airways Sentinel Network for airway diseases (MASK-air) app, we developed and validated an electronic daily asthma control score (e-DASTHMA). Methods: We used MASK-air data (freely available to users in 27 countries) to develop and assess different daily control scores for asthma. Data-driven control scores were developed based on asthma symptoms reported by a visual analogue scale (VAS) and self-reported asthma medication use. We included the daily monitoring data from all MASK-air users aged 16–90 years (or older than 13 years to 90 years in countries with a lower age of digital consent) who had used the app in at least 3 different calendar months and had reported at least 1 day of asthma medication use. For each score, we assessed construct validity, test–retest reliability, responsiveness, and accuracy. We used VASs on dyspnoea and work disturbance, EQ-5D-VAS, Control of Allergic Rhinitis and Asthma Test (CARAT), CARAT asthma, and Work Productivity and Activity Impairment: Allergy Specific (WPAI:AS) questionnaires as comparators. We performed an internal validation using MASK-air data from Jan 1 to Oct 12, 2022, and an external validation using a cohort of patients with physician-diagnosed asthma (the INSPIRERS cohort) who had had their diagnosis and control (Global Initiative for Asthma [GINA] classification) of asthma ascertained by a physician. Findings: We studied 135 635 days of MASK-air data from 1662 users from May 21, 2015, to Dec 31, 2021. The scores were strongly correlated with VAS dyspnoea (Spearman correlation coefficient range 0·68–0·82) and moderately correlated with work comparators and quality-of-life-related comparators (for WPAI:AS work, we observed Spearman correlation coefficients of 0·59–0·68). They also displayed high test–retest reliability (intraclass correlation coefficients range 0·79–0·95) and moderate-to-high responsiveness (correlation coefficient range 0·69–0·79; effect size measures range 0·57–0·99 in the comparison with VAS dyspnoea). The best-performing score displayed a strong correlation with the effect of asthma on work and school activities in the INSPIRERS cohort (Spearman correlation coefficients 0·70; 95% CI 0·61–0·78) and good accuracy for the identification of patients with uncontrolled or partly controlled asthma according to GINA (area under the receiver operating curve 0·73; 95% CI 0·68–0·78). Interpretation: e-DASTHMA is a good tool for the daily assessment of asthma control. This tool can be used as an endpoint in clinical trials as well as in clinical practice to assess fluctuations in asthma control and guide treatment optimisation. Funding: None. © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
  • No Thumbnail Available
    Item
    Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study
    (John Wiley and Sons Inc, 2025) Sousa-Pinto B.; Costa E.M.; Vieira R.J.; Klimek L.; Czarlewski W.; Pfaar O.; Bedbrook A.; Amaral R.; Brussino L.; Kvedariene V.; Larenas-Linnemann D.E.; Iinuma T.; Pham-Thi N.; Regateiro F.S.; Taborda-Barata L.; Ventura M.T.; Ansotegui I.J.; Bergmann K.C.; Canonica G.W.; Cardona V.; Cecchi L.; Cherrez-Ojeda I.; Cingi C.; Cruz A.A.; Del Giacco S.; Devillier P.; Fokkens W.J.; Gemicioglu B.; Haahtela T.; Ivancevich J.C.; Kuna P.; Kraxner H.; Laune D.; Louis R.; Makris M.; Morais-Almeida M.; Mösges R.; Niedoszytko M.; Papadopoulos N.G.; Patella V.; Pereira A.M.; Reitsma S.; Robles-Velasco K.; Rouadi P.W.; Samolinski B.; Sova M.; Toppila-Salmi S.K.; Sastre J.; Valiulis A.; Yorgancioglu A.; Zidarn M.; Zuberbier T.; Fonseca J.A.; Bousquet J.; Anto J.M.; Kupczyk M.; Kulus M.; Roche N.; Scichilone N.; Almeida R.; Bosnic-Anticevich S.; Braido F.; Loureiro C.C.; de Vries G.; Giuliano A.F.M.; Jácome C.; Kaidashev I.; Louis G.; Lourenço O.; Makela M.; Maurer M.; Mullol J.; Nadif R.; O’Hehir R.; Okamoto Y.; Ollert M.; Olze H.; Pétré B.; Puggioni F.; Romantowski J.; Rivero-Yeverino D.; Rodriguez-Gonzalez M.; Sá-Sousa A.; Savouré M.; Serpa F.S.; Shamji M.H.; Sheikh A.; Ulrik C.S.; Sofiev M.; Sperl A.; Todo-Bom A.; Tsiligianni I.; Valovirta E.; van Eerd M.; Blain H.; Boulet L.-P.; Brusselle G.; Buhl R.; Charpin D.; Casale T.; Chivato T.; Correia-de-Sousa J.; Corrigan C.; de Blay F.; Dykewicz M.; Fiocchi A.; Giovannini M.; Jassem E.; Jutel M.; Keil T.; La Grutta S.; Lipworth B.; Papi A.; Pépin J.-L.; Quirce S.; Cordeiro C.R.; Torres M.J.; Usmani O.S.; Bonini M.; Gradauskiene B.; Brightling C.
    Background: Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis. Methods: We included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom-medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data. Results: We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine-fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self-reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co-medication. The sensitivity analyses displayed similar results. Conclusions: A high adherence was found in patients reporting regular use of MASK-air. Different adherence patterns were found for INCS compared to OAH or azelastine-fluticasone that are likely to impact guidelines. © 2025 The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.